Symptomatic Treatment of Mild COVID-19 with Vitex negundo (NIRPROMP formulation): A Randomized, Controlled Clinical Trial

Main Article Content

Cecilia Maramba-Lazarte
Johannes Paulo Cerrado
Jaime Purificacion
Shelly Heredia
Daisy Mae Bagaoisan
Ruth Elio
Mary Christine Castro
Essel Tolosa
John Mark Velasco
Jocelyn Bautista-Palacpac
Jade Rodriguez

Abstract

There are few drugs available for the early treatment of mild COVID-19 infection. This study aimed to assess the efficacy and safety of Lagundi (Vitex negundo) tablets and syrup in patients with mild COVID-19 without comorbidities. This was a 2-stage multicenter parallel, randomized clinical trial. Stage 1 was a dose-finding study comparing high with standard-dose Lagundi. Stage 2 was the efficacy study using the dose chosen from stage 1 vs. placebo. Outcome measures included symptom scores, clinical recovery time, disease progression, global evaluation scales (GES), and time to negative RT-PCR. Lagundi and placebo treatments were given for 10 days. For stage 1, there was no significant difference in the time to recovery and global evaluation scales for the two dosage groups (n=75). Standard dose was chosen for the 2nd stage. In stage 2, baseline characteristics between Lagundi 600 mg three times a day (n=101) and the placebo (n=99) were not significantly different except for BMI. Total symptom scores (-8.0,95%:CI: -13.37,-2.62) and anosmia scores (-4.17,95%CI:-6.35,-1.98) at endline were significantly lower in the Lagundi group compared to the placebo when controlling for visit date and baseline scores signifying greater relief for Lagundi.  Scores for other symptoms were lower in the Lagundi group but were not significant. Physician- and patient-rated GES scores were higher for the Lagundi group than placebo (suggesting more relief) but were not statistically significant. RT PCR showed no significant differences between Lagundi and placebo on mean cycle threshold values for days 4, 8, and 12. The mean recovery time (overall and for symptoms) was not significantly different between the two groups. Adverse events were not significantly different between the intervention and placebo.

Article Details

Section
Research Articles

References

Worldometer: COVID-19 Coronavirus Pandemic. [cited 2022 Jun 12]. Available from: https://www. worldometers.info/coronavirus

World Health Organization. Therapeutics and COVID-19: living guideline, [cited 2022 Mar 22]. Available from: https://www.who.int/ publications/i/item/WHO-2019-nCoV-therapeutics-2022.4

Kim PS, Read SW, Fauci AS. Therapy for early COVID-19: a critical need. JAMA. 2020;324(21):2149–2150.

Mitjà O, Corbacho-Monné M, Ubals M, Tebé C, Peñafiel J, Tobias A, et al. Hydroxychloroquine for early treatment of adults with mild coronavirus disease 2019: a randomized, controlled trial. Clin Infect Dis. 2021 Dec 6;73(11):e4073-e4081.

López-Medina E, López P, Hurtado IC. Effect of Ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA. 2021;325(14):1426–1435.

Dayrit FM, Sarmiento Macahi RA, Calimag MMP, Maudlid DA. Encyclopedia of Common Medicinal Plants of the Philippines Vol 1. Philippine Institute of Traditional and Alternative Healthcare. 2014;354-355.

Maramba-Lazarte, CC, Cortes-Maramba N, Palacpac JB. Guidebook on the Proper Use of Medicinal Plants. 6th edition. Manila: Institute of Herbal Medicine;2017.

Department of Health Pharmaceutical Division. Philippine National Formulary. 8th edition. Manila: Department of Health; 2019.

Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. N Engl J Med. 2020 Oct 29;383(18):1757-1766.

Dharmasiri MG, Jayakody JR, Galhena G, Liyanage SS, Ratnasooriya WD. Anti-inflammatory and analgesic activities of mature fresh leaves of Vitex negundo. J Ethnopharmacol. 2003;87(2-3):199-206.

Pokala N, Alasyam N, Rasamal K. Evaluation and comparison of antipyretic activity of aqueous leaf extracts of Vitex negundo and Andrographis paniculata in rabbits. Natl J Physiol Pharm Pharmacol. 2019;9(6): 556-661.

Murthy JR, Venkataraman S, Meera R, Desmukh KS, Chidambaranathan N, Devi P. Phytochemical investigation and antipyretic activity of leaf extract of Vitex negundo Linn. Int. J. PharmTech Res.2010;2(2): 1068-1073.

Cayona R, Creencia E. Discovery of a "Cocktail" of potential SARS-COV-2 main protease inhibitors through virtual screening of known chemical components of Vitex negundo L.("Lagundi"). Med Chem. 2022 Mar 1;18(3):364-381.

Sivaraman D, Pradeep PS. Revealing antiviral potential of bio-active therapeutics targeting SARS-CoV2-polymerase (RdRp) in combating COVID-19: Mol Investig Indian Traditional Med, 2020;2020030450.

Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical–therapeutic staging proposal. The journal of heart and lung transplantation. 2020 May 1;39(5):405-407.

Subbed CP, Kruger M, Rutherford P, Gemmel L. Validation of a modified early warning score in medical admissions. Q J Med. 2001 Oct 1;94(10):521-526.

Huang JH, Su QM, Yang J, Lv YH, He YC, Chen JC, et al. Sample sizes in dosage investigational clinical trials: a systematic evaluation. Drug Des Devel Ther. 2015; 9:305.

Meng X, Deng Y, Dai Z, Meng Z. COVID-19, and anosmia: a review based on up-to-date knowledge. Am J Otolaryngol. 2020 Sep 1;41(5):102581.

von Bartheld CS, Hagen MM, Butowt R. Prevalence of chemosensory dysfunction in COVID-19 patients: a systematic review and meta-analysis reveals significant ethnic differences.: ACS Chem. Neurosci. 2020 Sep 1;11(19):2944-2961.

Butowt R, von Bartheld CS. Anosmia in COVID-19: underlying mechanisms and assessment of an olfactory route to brain infection. Neuroscientist. 2021 Dec;27(6): 582-603.

Ho CY, Salimian M, Hegert J, O'Brien J, Choi SG, Ames H, et al. Postmortem assessment of olfactory tissue degeneration and microvasculopathy in patients with COVID-19. JAMA Neurology. 2022;79(6): 544-553.

Chattopadhyay P, Hazarika S, Dhiman S, Upadhyay A, Pandey A, Karmakar S, et al. Vitex negundo inhibits cyclooxygenase-2 inflammatory cytokine-mediated inflammation on carrageenan-induced rat hind paw edema. Pharmacognosy Res. 2012 Jul;4(3): 134.

Tigno, TT, Francisco, AD. The comparative effects of purified fraction of Vitex negundo L (lagundi) and crude extracts of Cassia alata L. (akapulco) and Artemisia vulgaris L. (damong maria) on inflammatory processes in vitro. NRCP Research J. 1993;3(2):349-354.

Malik A, Anis I, Khan SB, Ahmed E, Ahmed Z, Nawaz SA, et al. Enzymes inhibiting lignans from Vitex negundo. Chem Pharm Bull. 2004;52(11):1269-1272.

Khan A, Naz S, Farooq U, Shahid M, Ullah I, Ali I, et al. Bioactive chromone constituents from Vitex negundo alleviate pain and inflammation. J Pain Res. 2018; 11:95.

Telang RS, Chatterjee S, Varshneya C. Study on analgesic and anti-inflammatory activities of Vitex negundo Linn. Indian J Pharmacol. 1999 Sep 1;31 (5):363.

Kulkarni RR, Virkar AD, D'mello P. Antioxidant and antiinflammatory activity of Vitex negundo. Indian J Pharm Sci. 2008 Nov;70(6):838-840.

Cordero RR, A comparative study of Lagundi and aspirin as analgesics for post-extraction pain. Phil Dental Assoc J. 1985; 35(1):16-18.

Miskin N, Manjunath KP, Bhandarkar A, Bolakatti G, Katagi MS. Antipyretic activity of Vitex negundo Linn leaves extracts. RGUHS J Pharm Sci. 2012;2(2): 78-81.

Dayrit F, Lagurin L. Identification of four iridoids in the pharmacologically-active fraction of Vitex negundo L. Philippine J Sci. 1994 Oct 1;123(4): 293-304.

Dayrit, F. Phytochemical Studies on Lagundi Leaves in Lagundi (Vitex negundoL.) Monograph. s.l.: Philippine Council for Health Research and Development Department of Science and Technology. Technical Report Series no. 6.;1989.

Khan M, Shah AJ, Gilani AH. Insight into the bronchodilator activity of Vitex negundo. Pharm Biol. 2015 Mar 4;53(3): 340-344.

Chu R. The effect of Lagundi (a local herb) tablets on bronchial asthma in adults: a randomized, double-blind study with theophylline. Phil Family Physician. 1988; 1:1-10.

Haq RU, Shah AU, Khan AU, Ullah Z, Khan HU, Khan RA, et al. Antitussive and toxicological evaluation of Vitex negundo. Nat Prod Res. 2012;26(5):484-488.

National Integrated Research Program on Medicinal Plants. Lagundi Tablet Technology Transfer Document. s.l.: Philippine Council for Health Research and Development;1994.

Alegado-Bagaoisan DM, Castro MC, Purificacion JM. A systematic review on Vitex negundo (NIRPROMP formulations) for the treatment of acute cough of mild to moderate severity in pediatric patients. Acta Medica Philippina. 2020 Feb 5;54(1): 36-41.

Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B. 2020 May 1;10(5):766-788.

NIH Testing for SARS-CoV-2 Infection Report Practice Guideline. - [s.l.]: National Institutes of Health;2021.

Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020 May 28; 382(22):2081-2090.

La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infec Dis. 2020 Jun;39(6):1059-1061.

Carmo A, Pereira-Vaz J, Mota V, Mendes A, Morais C, Coelho da Silva A, et al. Clearance and persistence of SARS Co-V2 RNA in Patients with COVID-19. J Med Virol. 2020; 92(10):2227-2231.

Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness:

a systematic review and meta-analysis. Lancet Microbe. 2021 Jan;2(1): e13-e22.

Center for Disease Control and Prevention. Ending Isolation and Precautions for People with COVID-19. [cited 2022 Jun 14]; Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html

Rao SN, Manissero D, Steele VR, Pareja J. A systematic review of the clinical utility of cycle threshold values in the context of COVID-19. Infect Dis Ther. 2020 Sep;9(3):573-586.